Rubella vaccine developer and History of Vaccines advisor Stanley A. Plotkin, MD, appeared on CSPAN’s Washington Journal to discuss the history of vaccination and the U.S. government’s role in regulating vaccines.
Stanley A. Plotkin, MD, vaccine developer and History of Vaccines advisor, will appear Thursday, 11/3, on C-SPAN’s Washington Journal around 9:15 am EDT. Dr. Plotkin will be discussing the history of vaccination and the role of the government in supporting research and regulating vaccine production.
The human papillomavirus (HPV) vaccine has been recommended as part of the routine vaccination schedule for girls aged 11-12 since 2006 for the prevention of cervical cancer. In 2009, the FDA licensed the vaccine for use in males aged 9-26 years for the prevention of genital warts caused by two types of HPV, but the vaccine was not yet recommended for boys as part of the routine immunization schedule.
On October 12, the Philadelphia Neurological Society held one of its regular meetings at The College of Physicians of Philadelphia and invited Paul A. Offit, MD, to speak to the membership.
A study published in the October 3, 2011, issue of the Journal of Clinical Oncology reveals a startling rise in the rate of throat cancers related to human papillomavirus (HPV). The study looked at specimens from 271 throat cancers (specifically oropharyngeal squamous cell carcinomas, or OPSCC) collected over 20 years.